SK8702001A3 - Cyclosporin solution - Google Patents
Cyclosporin solution Download PDFInfo
- Publication number
- SK8702001A3 SK8702001A3 SK870-2001A SK8702001A SK8702001A3 SK 8702001 A3 SK8702001 A3 SK 8702001A3 SK 8702001 A SK8702001 A SK 8702001A SK 8702001 A3 SK8702001 A3 SK 8702001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- cyclosporin
- solution
- weight
- anionic surfactant
- solution according
- Prior art date
Links
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims abstract description 79
- 108010036949 Cyclosporine Proteins 0.000 title claims abstract description 79
- 229930105110 Cyclosporin A Natural products 0.000 title claims abstract description 76
- 229960001265 ciclosporin Drugs 0.000 title claims abstract description 76
- 229930182912 cyclosporin Natural products 0.000 title claims abstract description 56
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 22
- 235000004866 D-panthenol Nutrition 0.000 claims abstract description 9
- 239000011703 D-panthenol Substances 0.000 claims abstract description 9
- 229960003949 dexpanthenol Drugs 0.000 claims abstract description 9
- 239000002736 nonionic surfactant Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- 239000003945 anionic surfactant Substances 0.000 claims description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- 239000003085 diluting agent Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 14
- 235000011187 glycerol Nutrition 0.000 claims description 8
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
- 230000035622 drinking Effects 0.000 claims description 7
- 239000007903 gelatin capsule Substances 0.000 claims description 7
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 239000002904 solvent Substances 0.000 abstract description 4
- 238000001556 precipitation Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 49
- 238000009472 formulation Methods 0.000 description 14
- 230000036765 blood level Effects 0.000 description 7
- -1 tetrahydrofurfuryl Chemical group 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229940068968 polysorbate 80 Drugs 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 108010036941 Cyclosporins Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229940063121 neoral Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000020354 squash Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine a Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940072106 hydroxystearate Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cephalosporin Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19859910A DE19859910C2 (de) | 1998-12-23 | 1998-12-23 | Orales Arzneimittel |
| PCT/EP1999/010358 WO2000038702A1 (de) | 1998-12-23 | 1999-12-23 | Cyclosporin-lösung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK8702001A3 true SK8702001A3 (en) | 2002-01-07 |
Family
ID=7892567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK870-2001A SK8702001A3 (en) | 1998-12-23 | 1999-12-23 | Cyclosporin solution |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1140135B1 (no) |
| JP (1) | JP2002533401A (no) |
| AT (1) | ATE249834T1 (no) |
| AU (1) | AU762963B2 (no) |
| CA (1) | CA2355271A1 (no) |
| CZ (1) | CZ20012143A3 (no) |
| DE (2) | DE19859910C2 (no) |
| DK (1) | DK1140135T3 (no) |
| ES (1) | ES2203235T3 (no) |
| HK (1) | HK1037140A1 (no) |
| HU (1) | HUP0104623A3 (no) |
| NO (1) | NO20012932D0 (no) |
| PL (1) | PL348180A1 (no) |
| PT (1) | PT1140135E (no) |
| RU (1) | RU2216342C2 (no) |
| SK (1) | SK8702001A3 (no) |
| WO (1) | WO2000038702A1 (no) |
| ZA (1) | ZA200104828B (no) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| DE102009037551A1 (de) | 2009-08-17 | 2011-02-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Cyclosporinderivate |
| DE102011111991A1 (de) | 2011-08-30 | 2013-02-28 | Lead Discovery Center Gmbh | Neue Cyclosporin-Derivate |
| US8957048B2 (en) | 2011-10-06 | 2015-02-17 | Allergan, Inc. | Compositions for the treatment of dry eye |
| US9907826B2 (en) | 2011-12-07 | 2018-03-06 | Allergan, Inc. | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8903804D0 (en) * | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
| CA2161004C (en) * | 1993-04-20 | 2004-10-26 | Wilfried Fischer | Active ingredient patch |
| US5603951A (en) * | 1994-11-09 | 1997-02-18 | Hanmi Pharm. Ind. Co., Ltd. | Cyclosporin-containing soft capsule compositions |
| US5798333A (en) * | 1996-09-17 | 1998-08-25 | Sherman; Bernard C. | Water-soluble concentrates containing cyclosporins |
| US6008192A (en) * | 1997-03-12 | 1999-12-28 | Abbott Laboratories | Hydrophilic binary systems for the administration of lipophilic compounds |
-
1998
- 1998-12-23 DE DE19859910A patent/DE19859910C2/de not_active Expired - Fee Related
-
1999
- 1999-12-23 EP EP99964670A patent/EP1140135B1/de not_active Expired - Lifetime
- 1999-12-23 PT PT99964670T patent/PT1140135E/pt unknown
- 1999-12-23 DE DE59907058T patent/DE59907058D1/de not_active Expired - Fee Related
- 1999-12-23 HU HU0104623A patent/HUP0104623A3/hu unknown
- 1999-12-23 DK DK99964670T patent/DK1140135T3/da active
- 1999-12-23 SK SK870-2001A patent/SK8702001A3/sk unknown
- 1999-12-23 ES ES99964670T patent/ES2203235T3/es not_active Expired - Lifetime
- 1999-12-23 RU RU2001120359/14A patent/RU2216342C2/ru not_active IP Right Cessation
- 1999-12-23 AU AU30434/00A patent/AU762963B2/en not_active Ceased
- 1999-12-23 JP JP2000590654A patent/JP2002533401A/ja active Pending
- 1999-12-23 CA CA002355271A patent/CA2355271A1/en not_active Abandoned
- 1999-12-23 AT AT99964670T patent/ATE249834T1/de not_active IP Right Cessation
- 1999-12-23 WO PCT/EP1999/010358 patent/WO2000038702A1/de not_active Application Discontinuation
- 1999-12-23 PL PL99348180A patent/PL348180A1/xx unknown
- 1999-12-23 CZ CZ20012143A patent/CZ20012143A3/cs unknown
-
2001
- 2001-06-13 ZA ZA200104828A patent/ZA200104828B/en unknown
- 2001-06-13 NO NO20012932A patent/NO20012932D0/no not_active Application Discontinuation
- 2001-11-07 HK HK01107803A patent/HK1037140A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE249834T1 (de) | 2003-10-15 |
| DE19859910C2 (de) | 2001-03-22 |
| HUP0104623A3 (en) | 2002-08-28 |
| NO20012932L (no) | 2001-06-13 |
| AU762963B2 (en) | 2003-07-10 |
| ZA200104828B (en) | 2002-09-13 |
| EP1140135A1 (de) | 2001-10-10 |
| CZ20012143A3 (cs) | 2002-01-16 |
| WO2000038702A1 (de) | 2000-07-06 |
| NO20012932D0 (no) | 2001-06-13 |
| HK1037140A1 (en) | 2002-02-01 |
| AU3043400A (en) | 2000-07-31 |
| PL348180A1 (en) | 2002-05-06 |
| EP1140135B1 (de) | 2003-09-17 |
| JP2002533401A (ja) | 2002-10-08 |
| DE19859910A1 (de) | 2000-06-29 |
| HUP0104623A2 (hu) | 2002-04-29 |
| DK1140135T3 (da) | 2003-12-08 |
| PT1140135E (pt) | 2003-12-31 |
| RU2216342C2 (ru) | 2003-11-20 |
| CA2355271A1 (en) | 2000-07-06 |
| DE59907058D1 (en) | 2003-10-23 |
| ES2203235T3 (es) | 2004-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2257917C2 (ru) | Самоэмульгирующиеся композиции для плохорастворимых в воде лекарственных препаратов | |
| FI116197B (fi) | Menetelmä farmaseuttisten koostumusten valmistamiseksi vaikeasti liukenevia aktiiviaineita varten | |
| RU2158601C2 (ru) | Новые лекарственные формы циклоспорина для орального применения с простым составом и высокой биодоступностью и способ их получения | |
| US6306434B1 (en) | Pharmaceutical composition comprising cyclosporin solid-state microemulsion | |
| US5614491A (en) | Liquid preparations containing cyclosporin and process for preparing same | |
| KR100342942B1 (ko) | 카르두스 마리아누스 추출물 또는 이로부터 정제된 실리빈을함유하는 경구용 마이크로에멀젼 조성물 | |
| HU215966B (hu) | Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum | |
| CZ301382B6 (cs) | Hydrofilní binární systémy pro podávání cyklosporinu | |
| JP2001505928A (ja) | シクロスポリン及び陰イオン性界面活性剤を含む固体医薬組成物 | |
| NZ528363A (en) | Liquid suspensions of posaconazole ( SCH 56592 ) with enhanced bioavailability for treating fungal infections | |
| JP2006508104A (ja) | 難溶性風邪薬の経口投与用マイクロエマルション濃縮液及びその製造方法 | |
| EP0706380B1 (en) | Encapsulated medicine | |
| US20020049158A1 (en) | Oral drug composition containing a verapamil derivative as a drug-absorption promotor | |
| FI115033B (fi) | Menetelmä rapamysiinikoostumuksien valmistamiseksi oraalisesti annettaviksi | |
| SK283442B6 (sk) | Farmaceutický prípravok na orálne podanie | |
| CZ306618B6 (cs) | Kompozice obsahující sloučeniny modafinylu | |
| US20020107183A1 (en) | Pharmaceutical preparations comprising cyclosporin for oral administration | |
| KR100308779B1 (ko) | 사이클로스포린을함유한신규조성물 | |
| SK8702001A3 (en) | Cyclosporin solution | |
| CA2255640A1 (en) | Pharmaceutical compositions containing cyclosporine and a carrier comprising at least an ester of alpha-glycerophosphoric acid | |
| KR20040047056A (ko) | 비페닐디메틸디카복실레이트의 경구용 마이크로에멀젼조성물 | |
| US5891456A (en) | Glyceryl monosterate based biodegradable implants for site-specific delivery of drugs | |
| KR100569595B1 (ko) | 가용성 심바스타틴의 연질캡슐제 조성물 및 그의제조방법 | |
| SK123299A3 (en) | Pharmaceutical compositions containing cyclosporin | |
| KR0173349B1 (ko) | 사이클로스포린-함유 고체 분산체 조성물 |